Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 36997 | 69 | 40.6 | 90% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 230 | 3 | P GLYCOPROTEIN//FMO3//TRIMETHYLAMINURIA | 49374 |
| 3464 | 2 | FLAVIN CONTAINING MONOOXYGENASE//FMO3//TRIMETHYLAMINURIA | 1499 |
| 36997 | 1 | NICLOSAMIDE//WNT SIGNALING INHIBITOR//50 GROWTH INHIBITION VALUE | 69 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | NICLOSAMIDE | authKW | 3356746 | 46% | 24% | 32 |
| 2 | WNT SIGNALING INHIBITOR | authKW | 885092 | 3% | 100% | 2 |
| 3 | 50 GROWTH INHIBITION VALUE | authKW | 442546 | 1% | 100% | 1 |
| 4 | AFFILIATED HOSP XIANGYA 2 | address | 442546 | 1% | 100% | 1 |
| 5 | CHAIR MED TEACHING MED EDUC | address | 442546 | 1% | 100% | 1 |
| 6 | ERK MNK EIF4E | authKW | 442546 | 1% | 100% | 1 |
| 7 | HEILONGJIANG MED SCITRANLAT MED COOPE | address | 442546 | 1% | 100% | 1 |
| 8 | INHIBITION OF CANONICAL AND NONCANONICAL WNT SIGNALING | authKW | 442546 | 1% | 100% | 1 |
| 9 | NITRO SUBSTITUTED BENZAMIDES | authKW | 442546 | 1% | 100% | 1 |
| 10 | SELECTIVE CHEMOTHERAPEUTIC EFFICACY | authKW | 442546 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Oncology | 481 | 43% | 0% | 30 |
| 2 | Cell Biology | 128 | 23% | 0% | 16 |
| 3 | Biochemistry & Molecular Biology | 46 | 25% | 0% | 17 |
| 4 | Pharmacology & Pharmacy | 38 | 16% | 0% | 11 |
| 5 | Chemistry, Medicinal | 20 | 6% | 0% | 4 |
| 6 | Materials Science, Biomaterials | 18 | 3% | 0% | 2 |
| 7 | Parasitiology | 12 | 3% | 0% | 2 |
| 8 | Biophysics | 12 | 6% | 0% | 4 |
| 9 | Immunology | 9 | 7% | 0% | 5 |
| 10 | Virology | 7 | 3% | 0% | 2 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | AFFILIATED HOSP XIANGYA 2 | 442546 | 1% | 100% | 1 |
| 2 | CHAIR MED TEACHING MED EDUC | 442546 | 1% | 100% | 1 |
| 3 | HEILONGJIANG MED SCITRANLAT MED COOPE | 442546 | 1% | 100% | 1 |
| 4 | ZHEJIANG PL ENZYMOL | 442546 | 1% | 100% | 1 |
| 5 | ABDOMINAL CANCCANC | 147514 | 1% | 33% | 1 |
| 6 | STATE PROV S BIOMED PHARMACEUT CHIN | 147514 | 1% | 33% | 1 |
| 7 | EPIGENET CANC STEM CELLS | 126438 | 3% | 14% | 2 |
| 8 | MAT PROC INTELLIGENT MFG | 88508 | 1% | 20% | 1 |
| 9 | PK PD CORE | 88508 | 1% | 20% | 1 |
| 10 | STATE PROV S BIOMED PHARMACEUT CHINAKEY L | 88508 | 1% | 20% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | MOLECULAR CANCER THERAPEUTICS | 1738 | 6% | 0% | 4 |
| 2 | BLOOD CANCER JOURNAL | 1498 | 1% | 0% | 1 |
| 3 | CHINESE JOURNAL OF CANCER | 1118 | 1% | 0% | 1 |
| 4 | INFLAMMATION RESEARCH | 630 | 3% | 0% | 2 |
| 5 | CURRENT CANCER DRUG TARGETS | 464 | 1% | 0% | 1 |
| 6 | INTERNATIONAL IMMUNOPHARMACOLOGY | 407 | 3% | 0% | 2 |
| 7 | PHARMACEUTICAL CHEMISTRY JOURNAL | 397 | 1% | 0% | 1 |
| 8 | INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 376 | 3% | 0% | 2 |
| 9 | JOURNAL OF VASCULAR RESEARCH | 366 | 1% | 0% | 1 |
| 10 | JOURNAL OF FOOD AND DRUG ANALYSIS | 328 | 1% | 0% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | LI, ZH , YU, YF , SUN, SX , QI, BW , WANG, WY , YU, AX , (2015) NICLOSAMIDE INHIBITS THE PROLIFERATION OF HUMAN OSTEOSARCOMA CELL LINES BY INDUCING APOPTOSIS AND CELL CYCLE ARREST.ONCOLOGY REPORTS. VOL. 33. ISSUE 4. P. 1763 -1768 | 16 | 57% | 5 |
| 2 | MOOK, RA , WANG, JB , REN, XR , CHEN, MY , SPASOJEVIC, I , BARAK, LS , LYERLY, HK , CHEN, W , (2015) STRUCTURE-ACTIVITY STUDIES OF WNT/BETA-CATENIN INHIBITION IN THE NICLOSAMIDE CHEMOTYPE: IDENTIFICATION OF DERIVATIVES WITH IMPROVED DRUG EXPOSURE.BIOORGANIC & MEDICINAL CHEMISTRY. VOL. 23. ISSUE 17. P. 5829 -5838 | 20 | 43% | 3 |
| 3 | MONIN, MB , KRAUSE, P , STELLING, R , BOCUK, D , NIEBERT, S , KLEMM, F , PUKROP, T , KOENIG, S , (2016) THE ANTHELMINTIC NICLOSAMIDE INHIBITS COLORECTAL CANCER CELL LINES VIA MODULATION OF THE CANONICAL AND NONCANONICAL WNT SIGNALING PATHWAY.JOURNAL OF SURGICAL RESEARCH. VOL. 203. ISSUE 1. P. 193 -205 | 17 | 40% | 2 |
| 4 | AREND, RC , LONDONO-JOSHI, AI , GANGRADE, A , KATRE, AA , KURPAD, C , LI, YH , SAMANT, RS , LI, PK , LANDEN, CN , YANG, ES , ET AL (2016) NICLOSAMIDE AND ITS ANALOGS ARE POTENT INHIBITORS OF WNT/BETA-CATENIN, MTOR AND STAT3 SIGNALING IN OVARIAN CANCER.ONCOTARGET. VOL. 7. ISSUE 52. P. 86803 -86815 | 18 | 43% | 0 |
| 5 | ZHIRNIK, AS , SEMOCHKINA, YP , MOSKALEVA, EY , PEREVOZCHIKOVA, VG , RODINA, AD , SEVERIN, SE , (2016) ANTIPROLIFERATIVE ACTIVITY OF NICLOSAMIDE AGAINST MELANOMA AND COLORECTAL CANCER CELLS.PHARMACEUTICAL CHEMISTRY JOURNAL. VOL. 50. ISSUE 7. P. 471 -474 | 10 | 67% | 0 |
| 6 | LI, YH , LI, PK , ROBERTS, MJ , AREND, RC , SAMANT, RS , BUCHSBAUM, DJ , (2014) MULTI-TARGETED THERAPY OF CANCER BY NICLOSAMIDE: A NEW APPLICATION FOR AN OLD DRUG.CANCER LETTERS. VOL. 349. ISSUE 1. P. 8-14 | 17 | 24% | 38 |
| 7 | LIAO, Z , NAN, GX , YAN, ZJ , ZENG, LY , DENG, YL , YE, JX , ZHANG, ZL , QIAO, M , LI, RF , DENDULURI, S , ET AL (2015) THE ANTHELMINTIC DRUG NICLOSAMIDE INHIBITS THE PROLIFERATIVE ACTIVITY OF HUMAN OSTEOSARCOMA CELLS BY TARGETING MULTIPLE SIGNAL PATHWAYS.CURRENT CANCER DRUG TARGETS. VOL. 15. ISSUE 8. P. 726 -738 | 16 | 25% | 7 |
| 8 | CHEON, YH , KIM, JY , BAEK, JM , AHN, SJ , SO, HS , OH, J , (2016) NICLOSAMIDE SUPPRESSES RANKL-INDUCED OSTEOCLASTOGENESIS AND PREVENTS LPS-INDUCED BONE LOSS.BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. VOL. 470. ISSUE 2. P. 343 -349 | 11 | 34% | 0 |
| 9 | YANG, FF , YE, TH , LIU, ZH , FANG, AP , LUO, Y , WEI, W , LI, YJ , LI, YL , ZENG, AQ , DENG, YL , ET AL (2016) NICLOSAMIDE INDUCES COLORECTAL CANCER APOPTOSIS, IMPAIRS METASTASIS AND REDUCES IMMUNOSUPPRESSIVE CELLS IN VIVO.RSC ADVANCES. VOL. 6. ISSUE 107. P. 106019 -106030 | 12 | 29% | 0 |
| 10 | LI, SL , YAN, J , ZHANG, YQ , ZHEN, CL , LIU, MY , JIN, J , GAO, JL , XIAO, XL , SHEN, X , TAI, Y , ET AL (2017) NICLOSAMIDE ETHANOLAMINE INHIBITS ARTERY CONSTRICTION.PHARMACOLOGICAL RESEARCH. VOL. 115. ISSUE . P. 78 -86 | 9 | 36% | 0 |
Classes with closest relation at Level 1 |